Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials.

Authors:
Chuang MH; Chen IW; Chen JY; Kang FC; Ho CN and 4 more

Journal:
Eur Respir Rev

Publication Year: 2023

DOI:
10.1183/16000617.0219-2022

PMCID:
PMC10189640

PMID:
37197770

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Eur Respir Rev

Abbreviation: Eur Respir Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
An update on diagnosis and management of obstructive sleep apnoea in the first 2 years of life.
Polytarchou A; Moudaki A; Van de Perck E and 4 more (2024) - Transparency Score: 2/6
Clinical-imaging-pathological correlation in pulmonary hypertension associated with left heart dise…
van de Veerdonk MC; Roosma L; Trip P and 4 more (2024) - Transparency Score: 2/6
Eradication treatment for <i>Pseudomonas aeruginosa</i> infection in adults with bronchiectasis: a …
Conceição M; Shteinberg M; Goeminne P and 2 more (2024) - Transparency Score: 3/6
From treatable traits to GETomics in airway disease: moving towards clinical practice.
Papi A; Faner R; Pavord I and 6 more (2024) - Transparency Score: 3/6
Lung cancer risk and occupational pulmonary fibrosis: systematic review and meta-analysis.
Krabbe J; Steffens KM; Drießen S and 1 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest: The authors declare no conflicts of interest."

Funding Disclosure
Evidence found in paper:

"We registered the protocol of the current meta-analysis with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42022358694). This research adhered to the Preferred Reporting Items Systematic Reviews and Meta-Analysis (PRISMA) guidelines (www.prisma-statement.org)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025